10X Genomics, Inc.

10X Genomics, Inc. has recently experienced a stock price decline, reflecting its complex market dynamics. While the company has outperformed the S&P 500 over the past year, it has faced significant challenges in longer-term performance. Technical indicators present mixed signals, indicating varying market sentiments.

10X Genomics, Inc. has shown notable market activity, gaining 12.56% today and reaching an intraday high of USD 22.17. The company has achieved a 15.32% increase over the past week and an impressive 89.96% return over the last year, significantly outperforming the S&P 500.

10X Genomics, Inc. has recently revised its evaluation amid notable stock price fluctuations, currently at $22.13. The company has achieved a nearly 90% return over the past year, significantly outperforming the S&P 500. Technical indicators show mixed performance, with some bullish trends and neutral momentum signals.

10X Genomics, Inc. saw a notable stock price increase on November 7, 2025, amid a modest rise in the broader market. The company has shown strong weekly and monthly performance, despite a decline over the past year. High institutional ownership reflects investor confidence, while challenges remain with negative EBITDA.

10X Genomics, Inc. experienced a notable stock price increase on October 31, 2025, despite facing a challenging year with a significant decline. The company has high institutional ownership but struggles with negative financial metrics, indicating ongoing profitability issues amid a volatile market environment.

10X Genomics, Inc. has recently seen a stock price of $11.60, reflecting volatility over the past year with a high of $18.21 and a low of $6.78. The company has faced significant challenges, with a notable decline in stock performance compared to the S&P 500 over various timeframes.

10X Genomics, Inc. has faced significant stock price declines, with a year-to-date drop of 19.22% and a 41.5% decrease over the past year. Despite reporting strong operating cash flow and high institutional ownership, the company struggles with negative EBITDA and long-term underperformance compared to the S&P 500.

10X Genomics, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock price at $13.04. Over the past year, the company has experienced significant volatility, reflected in a return of -44.46%. Technical indicators show mixed signals, highlighting the need for careful performance monitoring.